Professional · Issue 3 · 2026-10-04
Mental Health Burden Persists in Youth With CF and Their Caregivers Despite ETI Era
Editorially reviewed research summaries, context, and limitations.
Christina L Duncan, Megan von Isenburg, Angela Green, et al.
Summary: This multicenter cross-sectional study examined mental and behavioral health symptoms in 118 youth with cystic fibrosis (ages 7–17) on elexacaftor/tezacaftor/ivacaftor (ETI) and their caregivers across 11 U.S. CF centers. Clinically elevated depressive and anxiety symptoms were found in roughly one-quarter to one-third of both caregivers and youth. Sleep disturbance was flagged in nearly a third of youth, and caregiver mental health scores were meaningfully correlated with child mental health scores. The authors conclude that routine mental health screening remains warranted even in the ETI era, and that family-based approaches deserve consideration.
Why it matters: ETI has transformed the physical trajectory of CF, but the assumption that improved lung function automatically resolves psychosocial burden has not been consistently supported — and this study adds structured, multi-site data reinforcing that point. The caregiver–child correlation is particularly actionable: it suggests that screening only the patient, while ignoring the caregiver, may leave a significant source of risk unaddressed. For CF care teams and policymakers, this argues for maintaining — and possibly expanding — integrated mental health services rather than scaling them back in the wake of therapeutic success.
Expert perspective: The study is modest in scope but methodologically reasonable for a cross-sectional prevalence inquiry. The use of standardized, validated screening instruments across 11 centers strengthens comparability, though the authors do not report how centers were selected, raising questions about whether the sample skews toward academic or comprehensive care programs. With only 118 participants, confidence intervals are wide (e.g., childhood anxiety prevalence 95% CI: 18–44%), limiting precision and making subgroup conclusions tentative.
The cross-sectional design is the most important limitation. It cannot establish whether the observed mental health burden predates ETI, emerged independently of CF severity, or represents a residual effect already declining. Without a pre-ETI baseline or a comparator group not on ETI, it is impossible to determine whether rates are higher, lower, or unchanged relative to the pre-modulator era. The caregiver–child correlations (ρ = 0.20–0.52) span a wide range of effect sizes, and shared-method variance — caregivers completing proxy reports about the child — likely inflates some correlations, a limitation not discussed. The prevalence figures — approximately 23–29% for depression and 19–31% for anxiety — are broadly comparable to rates reported in youth with other chronic conditions and in the general adolescent population, particularly post-pandemic. Without a contemporaneous comparator, it is difficult to attribute these rates specifically to CF burden versus broader societal trends in youth mental health.
On the positive side, the inclusion of ADHD, externalizing behaviors, and sleep disturbance — affecting nearly 30–35% of youth — adds meaningful breadth beyond anxiety and depression alone and aligns with other CF research. The practical implication — that CF programs should continue routine mental health screening and consider family-based models — is reasonable and grounded in the data. This is useful incremental evidence that reinforces existing clinical guidance with contemporary, ETI-era data, which has real operational value for programs reassessing their psychosocial service models in a changed therapeutic landscape.
Relevance: Cystic Fibrosis
Source: https://pubmed.ncbi.nlm.nih.gov/42621765/
---